Stool DNA Analysis Cost-effective Check for Colon Cancer in Ulcerative Colitis Patients

Stool DNA Analysis Cost-effective Check for Colon Cancer in Ulcerative Colitis Patients
A recent study indicated that while colorectal cancer (CRC) surveillance in patients with ulcerative colitis was generally cost effective, the addition of stool DNA analysis to surveillance colonoscopy was the most cost-effective approach. If a stool DNA test is positive, then a colonoscopy would be performed, the researchers said. The study, “Stool DNA Analysis is Cost Effective for Colorectal Cancer Surveillance in Patients with Ulcerative Colitis,” was published in the journal Clinical Gastroenterology and Hepatology. “Surveillance colonoscopy has been considered standard of care for ulcerative colitis patients, based on observational (non-randomized) studies showing reduced incidence of colorectal cancer and earlier stage of CRC detected by this practice,”  Dr. John B. Kisiel, MD, of the division of gastroenterology and hepatology at the Mayo Clinic in Rochester, Minnesota, said in a
Subscribe or to access all post and page content.